Bridgebio Pharma (BBIO) closed at $76.03 on November 20, 2026, down 2.8% from the previous close, on volume of 1,364,851 shares (30-day average 2,706,979).
Data as of November 20, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 19, 2026 | Call with Delta Hedge | 19-Feb-27 80 C +79,500 Stock | 1,500 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 19, 2026. See the largest for 5, 30, 60 and 90 days
Piper Sandler Sticks to Its Buy Rating for BridgeBio Pharma (BBIO)
TipRanks (Fri, 20-Nov 7:05 AM ET)
Globe Newswire (Tue, 17-Nov 7:30 AM ET)
Globe Newswire (Wed, 11-Nov 7:30 AM ET)
BridgeBio to Participate in November and December Investor Conferences
Globe Newswire (Mon, 9-Nov 7:30 AM ET)
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Fri, 6-Nov 4:01 PM ET)
Globe Newswire (Tue, 3-Nov 7:30 AM ET)
BridgeBio Reports Third Quarter 2026 Financial Results and Corporate Updates
Globe Newswire (Thu, 29-Oct 4:01 PM ET)
Globe Newswire (Thu, 22-Oct 7:30 AM ET)
Globe Newswire (Sun, 11-Oct 2:30 PM ET)
Globe Newswire (Sun, 11-Oct 11:42 AM ET)
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. Its key drug is Attruby (acoramidis), an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
Bridgebio Pharma trades on the NASDAQ stock market under the symbol BBIO.
As of November 20, 2026, BBIO stock price declined to $76.03 with 1,364,851 million shares trading.
BBIO has a beta of 0.08, meaning it tends to be less sensitive to market movements. BBIO has a correlation of 0.00 to the broad based SPY ETF.
BBIO has a market cap of $14.81 billion. This is considered a Large Cap stock.
Last quarter Bridgebio Pharma reported $353 million in Revenue and -$.42 earnings per share. This beat revenue expectation by $57 million and exceeded earnings estimates by $.15.
In the last 3 years, BBIO traded as high as $93.42 and as low as $21.62.
The top ETF exchange traded funds that BBIO belongs to (by Net Assets): VTI, VB, VBK, XBI, VXF.
BBIO has outperformed the market in the last year with a price return of +16.0% while the SPY ETF gained +5.2%. BBIO has also outperformed the stock market ETF in the last 3 month and 2 week periods returning -9.4% and +2.4%, respectively, while the SPY returned -10.1% and -5.9%, respectively.
BBIO support price is $76.32 and resistance is $80.04 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BBIO shares will trade within this expected range on the day.